Physician profile
David Seth Share
NPI 1750330015
$803.08
in general payments reported to CMS, 2019-2025
14 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $217 · 2024: $376 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.57 | 2023-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $130.07 | 2023-2025 | Ubrelvy |
| Pfizer INC. | $101.43 | 2023-2024 | |
| Gilead Sciences, INC. | $83.18 | 2025 | |
| Inspire Medical Systems, INC. | $60.97 | 2024-2025 | Inspire |
| Eisai INC. | $52.39 | 2023-2024 | |
| Amgen INC. | $49.34 | 2024 | Evenity, Prolia, Repatha |
| Seqirus USA INC | $32.86 | 2024 | Fluad, Flucelvax |
| Sanofi-Aventis U.S. LLC | $31.50 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.02 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $20.69 | 2024 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $18.62 | 2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.24 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Share listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.